Latest Period
Q1 2026
Security Snapshot
Krystal Biotech, Inc. - Common Stock, $0.00001 par value ("Common Stock") (KRYS) Institutional Ownership
CUSIP: 501147102
13F Institutional Holders and Ownership History from Q3 2017 to Q1 2026
Institutions Reporting
365
Shares (Excl. Options)
28,364,487
Price
$258.32
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, $0.00001 par value ("Common Stock")
- Symbol
- KRYS on Nasdaq
- Shares outstanding
- 29,463,330
- Price per share
- $276.50
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 28,364,487
- Total reported value
- $7,321,689,287
- % of total 13F portfolios
- 0.01%
- Share change
- -197,970
- Value change
- -$43,752,733
- Number of holders
- 365
- Price from insider filings
- $276.50
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- KRYS - Krystal Biotech, Inc. - Common Stock, $0.00001 par value ("Common Stock") is tracked under CUSIP 501147102.
- 365 institutions reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 332 to 365 between Q4 2025 and Q1 2026.
- Reported value moved from $7,006,787,204 to $7,321,689,287.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 365 institutions filings for Q1 2026.
Security key
501147102
Latest holder period
Q1 2026
13F holders
365
13D/G owners
3
CIK / CUSIP context first
Open Q1 2026 holders
KRYS full holder history
Krystal Biotech, Inc. SEC filings
Krystal Biotech, Inc. company facts
Krystal Biotech, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 501147102:
Significant Owners of Krystal Biotech, Inc. - Common Stock, $0.00001 par value ("Common Stock") (KRYS) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Krishnan Krish S | 12% | $906,060,757 | 3,388,283 | Krish S. Krishnan | 31 Mar 2026 | |||
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5% | $382,084,101 | 1,479,111 | Vanguard Portfolio Management | 31 Mar 2026 | |||
| STATE STREET CORP | 4.4% | $218,154,766 | 1,278,975 | STATE STREET CORPORATION | 31 Dec 2024 |
As of 31 Mar 2026, 365 institutional investors reported holding 28,364,487 shares of Krystal Biotech, Inc. - Common Stock, $0.00001 par value ("Common Stock") (KRYS). This represents 96% of the company’s total 29,463,330 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Krystal Biotech, Inc. - Common Stock, $0.00001 par value ("Common Stock") (KRYS) together control 80% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 4,373,987 | +0.56% | 0.06% | $1,129,888,252 |
| BlackRock, Inc. | 13% | 3,940,456 | +0.07% | 0.02% | $1,017,898,595 |
| Avoro Capital Advisors LLC | 9.8% | 2,888,888 | 0% | 7.4% | $746,257,548 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.9% | 1,456,727 | 0% | 0.02% | $376,301,719 |
| STATE STREET CORP | 4.5% | 1,314,434 | -2.1% | 0.01% | $339,544,591 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4% | 1,165,324 | 0% | 0.01% | $301,026,496 |
| Soleus Capital Management, L.P. | 3.9% | 1,153,087 | +23% | 12% | $297,865,434 |
| Capital World Investors | 2.8% | 824,720 | +1.9% | 0.03% | $213,041,670 |
| Redmile Group, LLC | 2.3% | 673,505 | -0.62% | 12% | $173,979,812 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.2% | 643,975 | +5.2% | 0.01% | $166,383,833 |
| Hood River Capital Management LLC | 2.1% | 619,586 | +1% | 1.6% | $160,051,456 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.6% | 485,074 | -8.5% | 0.01% | $125,305,000 |
| Bellevue Group AG | 1.6% | 481,785 | +17% | 3% | $124,454,701 |
| Frazier Life Sciences Management, L.P. | 1.6% | 481,307 | -1.5% | 3.2% | $124,331,224 |
| DIMENSIONAL FUND ADVISORS LP | 1.6% | 468,990 | -4.9% | 0.03% | $121,130,310 |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 1.4% | 407,178 | +8.2% | 0.35% | $105,182,221 |
| FIRST TRUST ADVISORS LP | 1.2% | 350,521 | +43% | 0.06% | $90,546,584 |
| JANUS HENDERSON GROUP PLC | 0.91% | 266,659 | +22% | 0.03% | $68,878,997 |
| BANK OF AMERICA CORP /DE/ | 0.88% | 260,647 | +37% | 0% | $67,330,333 |
| NORTHERN TRUST CORP | 0.86% | 252,463 | +2% | 0.01% | $65,216,242 |
| Invesco Ltd. | 0.85% | 251,373 | +319% | 0.01% | $64,934,673 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.82% | 241,986 | -0.32% | 0.01% | $62,509,824 |
| GOLDMAN SACHS GROUP INC | 0.73% | 214,949 | -27% | 0.01% | $55,525,626 |
| MORGAN STANLEY | 0.71% | 209,082 | -5.6% | 0% | $54,010,448 |
| BRAIDWELL LP | 0.62% | 182,425 | -9.7% | 1.6% | $47,124,026 |
Institutional Holders of Krystal Biotech, Inc. - Common Stock, $0.00001 par value ("Common Stock") (KRYS) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 28,364,487 | $7,321,689,287 | -$43,752,733 | $258.32 | 365 |
| 2025 Q4 | 28,422,218 | $7,006,787,204 | +$81,339,251 | $246.54 | 332 |
| 2025 Q3 | 27,965,722 | $4,936,825,964 | +$84,621,791 | $176.53 | 281 |
| 2025 Q2 | 27,659,439 | $3,802,977,476 | -$846,440 | $137.46 | 274 |
| 2025 Q1 | 27,342,861 | $4,929,918,497 | -$51,223,771 | $180.30 | 298 |
| 2024 Q4 | 27,774,030 | $4,351,782,009 | -$92,533,890 | $156.66 | 264 |
| 2024 Q3 | 28,280,954 | $5,147,915,246 | -$55,463,849 | $182.03 | 281 |
| 2024 Q2 | 28,529,838 | $5,239,051,095 | +$658,436,118 | $183.64 | 245 |
| 2024 Q1 | 25,223,190 | $4,487,798,716 | +$175,442,652 | $177.93 | 233 |
| 2023 Q4 | 24,418,337 | $3,029,453,570 | +$42,716,131 | $124.06 | 194 |
| 2023 Q3 | 23,797,985 | $2,760,663,293 | +$92,606,023 | $116.00 | 187 |
| 2023 Q2 | 23,039,160 | $2,704,675,917 | +$256,730,169 | $117.40 | 182 |
| 2023 Q1 | 20,979,177 | $1,678,957,589 | +$9,326,151 | $80.06 | 159 |
| 2022 Q4 | 20,961,146 | $1,660,575,264 | -$15,716,124 | $79.22 | 153 |
| 2022 Q3 | 20,879,536 | $1,455,390,527 | +$2,509,281 | $69.70 | 141 |
| 2022 Q2 | 20,782,487 | $1,364,495,044 | +$17,501,639 | $65.66 | 129 |
| 2022 Q1 | 20,551,109 | $1,367,525,309 | +$24,889,158 | $66.54 | 129 |
| 2021 Q4 | 19,309,579 | $1,350,723,574 | +$209,084,528 | $69.95 | 135 |
| 2021 Q3 | 16,287,424 | $850,358,590 | -$12,114,445 | $52.21 | 112 |
| 2021 Q2 | 16,400,636 | $1,115,239,700 | -$7,228,383 | $68.00 | 113 |
| 2021 Q1 | 16,474,358 | $1,268,577,569 | +$201,515,888 | $77.04 | 113 |
| 2020 Q4 | 13,913,023 | $835,272,340 | -$16,214,267 | $60.00 | 107 |
| 2020 Q3 | 14,383,109 | $619,123,442 | +$11,279,105 | $43.05 | 98 |
| 2020 Q2 | 14,124,381 | $585,026,548 | +$106,373,347 | $41.42 | 108 |
| 2020 Q1 | 11,507,819 | $497,600,700 | -$9,385,943 | $43.24 | 88 |
| 2019 Q4 | 11,391,925 | $630,888,478 | +$15,766,941 | $55.38 | 89 |
| 2019 Q3 | 11,182,639 | $388,328,616 | +$48,273,351 | $34.73 | 83 |
| 2019 Q2 | 9,765,134 | $393,197,420 | +$130,560,730 | $40.27 | 75 |
| 2019 Q1 | 6,652,555 | $218,869,000 | +$15,470,940 | $32.90 | 56 |
| 2018 Q4 | 6,208,589 | $129,016,000 | +$73,086,744 | $20.78 | 45 |
| 2018 Q3 | 2,717,290 | $47,597,000 | +$6,006,830 | $17.58 | 21 |
| 2018 Q2 | 2,390,244 | $35,543,000 | -$7,828,421 | $14.87 | 16 |
| 2018 Q1 | 3,076,255 | $31,040,000 | -$1,629,988 | $10.09 | 12 |
| 2017 Q4 | 3,236,349 | $34,047,000 | +$1,027,245 | $10.52 | 13 |
| 2017 Q3 | 3,142,571 | $31,331,000 | +$31,331,000 | $9.97 | 13 |